Bruker Corporation (NASDAQ: BRKR)

Bruker CALID Group update

Juergen Srega, President, Bruker CALID GroupJune 2, 2015

Bruker CALID roadmap to success

Streamline Business and Operating Model

Exit Products

Exit Factories

Outsource

Quality

Lean Ops

Commercial Ops

Invest in high-value positions

MALDI BioTyper

- Geo-Expansion

- Capabilities

- Claim-Expansion

- New Indications

- Replacement

- Consumables

New Products

UHR QTOF Portfolio

MALDI Portfolio

- MBT SMART

- rapifleX

- MPP PharmaPulse

FTIR & NIR

IMS/ETD Solutions

© Bruker Corporation

Bruker CALID update

3© Bruker Corporation

• Great progress made in streamlining the portfolio and footprint

Divested GC and ICP product lines

Eliminated one division organization

Exited 4 factories across the divisions

Closed all machine shops

Outsourced most of low-level assembly work

• Significant YoY improvements on GM and OM

Clinical expansion

MBT Microbial ID global expansion

MBT Microbial expansion beyond ID into AST

(resistance testing) and Food and Pharma

MTT MALDI TissueTyper

ToxTyper adoption in toxicology testing labs

Triple Quad MS assay expansion

Assays and Consumables

MALDI assays and consumables

New Biomarker ImunoMALDI assays

Bruker CALID Growth Platform

Clinical MALDI

© Bruker Corporation

Microscopy and Imaging portfolio

Raman microscopes and imaging techniques

FTIR microscopes and imaging techniques

rapifleX all new MALDI Tof instrument and imaging

technique

MS Processing

Global MBT Sites (May 2015)

Globally: 1682Europe: 957

Americas: 335

Asia/Pacific: 348

IMEA: 42

5

MALDI Biotyper References

Regulatory Affairs:

Libraries of MBT

6

0

500

1000

1500

2000

2500

FDA IVD FDA Claim 1 FDA Claim 2 FDA Total IVD

Vitek-MS MBT

• MBT is leading by far for IVD-CE systems

• MBT is also leading concerning US FDA-cleared species

• MBT is covering now 280 species for US-FDA in total

• 98% coverage of the typical bacterial identification

workflow of clinical microbiology laboratories

Mycobacteria Library 3.0

A Quantum Leap in Mycobacteria IDMycobacteria Library 3.0 for MALDI Biotyper®

• Contains almost all described

Mycobacteria species (149 entries)

• Excellent coverage of strain variation

• Several hundred references from well

characterized isolates by 24

cooperation partners in 9 countries

• Launch at ASM 2015 on June 1, 2015

7For Research Use Only. Not for Use in Diagnostic Procedures

All new MALDI TissueTyper rapifleX –

Expanding into clinical pathology

8

rapifleX™• Game-changing instrument for early

markets

• Proprietary 10 kHz smartbeam® laser

• Substantially improved image quality!

• Early wins with the MTT based on

rapifleX

• Introduction at ASMS 2015 in St. Louis

© Bruker Corporation

Pharma HTS workflow solution

MALDI PharmaPulse™

9© Bruker Corporation

• Fast to meet the needs of true HTS applications (less than 1 sec per sample) and replace Fluorescence • 10-100 times faster than multiplexed

LC/SPE-MS

• Label free detection accelerates assay development, reduces complexity of screening and potentially minimizes artifacts from label interference

• Low consumable costs (and less waste) since it uses 100x less solvent than multiplexed LC/SPE-MS• No need for SPE cartridges or LC columns!

February 2011

10 Bruker Confidential2. Juni 2015 10© Copyright Bruker Corporation. All rights reserved